对研究罕见疾病治疗效果的外部控制:挑战和未来方向
Janick Weberpals1, Shirley V Wang1
1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Clinical pharmacology and therapeutics
|September 17, 2024
概括
来自现实世界的数据的外部控制臂有助于评估罕见疾病治疗方法. 方法上存在挑战,但本次审查探讨了有效比较的解决方案.
科学领域:
- 药物监督 药物监督 药物监督
- 临床试验设计 临床试验设计
- 现实世界的证据.
背景情况:
- 监管机构越来越多地使用来自常规医疗保健数据的真实世界证据 (RWE) 来评估新疗法.
- 来自RWE的外部控制臂对于增加罕见疾病的单臂临床试验至关重要.
- 方法上的局限性可能会影响基于RWE的外部控制臂比较的有效性.
研究的目的:
- 审查在罕见疾病研究中利用外部控制臂的常用方法.
- 识别和讨论与这些方法相关的关键方法挑战.
- 提出未来的方向,以提高基于RWE的外部控制器的有效性.
主要方法:
- 对构建外部控制臂的常用方法的文献综述.
- 分析现有研究中报告的关键批评和局限性.
- 对未来研究的潜在解决方案和最佳实践的综合.
主要成果:
- 总结了RWE衍生的外部控制臂的共同方法.
- 突出了影响数据解释的重大方法问题.
- 确定了需要进一步研究和开发的领域.
结论:
- 外部控制臂提供了宝贵的见解,但需要仔细考虑方法.
- 解决发现的批评对于可靠的RWE利用在罕见病药物评估中至关重要.
- 未来的研究应该专注于强大的方法,以确保真实世界的数据比较的有效性.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Comparing the Survival Analysis of Two or More Groups
162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Hazard Ratio
96
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
96


